I think your theory is very likely GermanCol. Thank you so much for the excellent response. I agree on the possible issue there with the patients who may have been pseudo and not actual Progressors, it is very possible.
They also had that compassionate arm at one point for the rapid Progresso's who did not qualify for the trial. So the company has a bunch of different potential arms to add data for the FDA and other regulators to review. And we have not seen any of this data in aggregate, which the regulators will see. Not sure if those would even make it into the final publication as it's just an entirely different set of patients and details and it would confuse matters. But clearly the company has a lot of additional data.
I am hoping that all together, it will basically blow the socks off of all the regulators in terms of OS and improvement in quality of life also. If those patients also could have gotten Poly ICLC as an adjuvant and Keytruda, just imagine what might have been. There will be a lot of opportunity to further expand and improve results going forward as the doctors come to understand the full depth and breadth of the immune response and immune pathologies of the disease. Isn't it amazing that years ago, doctors would have cut tumors out and studied just the cells trying to figure out all of these details and now they know that it's so much more complicated than just the cells and mutations, but involves all the different bodily responses and autoimmune defenses and so much more than just getting the main tumor cells to die.
News 
Market Data 
Discover 
